ACUTA CAPITAL PARTNERS, LLC — 13F Holdings

2026 Q1  ·  36 Positions

2026 Q1 Portfolio Activity

In 2026 Q1, ACUTA CAPITAL PARTNERS, LLC maintained a portfolio of 36 distinct positions. The most significant new addition was ERASCA INC, now representing 4.05% of the total fund value. They heavily accumulated shares in TANGO THERAPEUTICS INC, increasing the position by 56.3%. Conversely, ACUTA CAPITAL PARTNERS, LLC completely exited their position in CIDARA THERAPEUTICS INC.
Position History hover any row below to update
Loading…
PCA Score Concentration Risk
Risk ENB
Total Positions
36
Quarter
2026 Q1
Top Holding
PRAX (19.3%)
Top 10 Concentration
77.4%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-36 of 36

ACUTA CAPITAL PARTNERS, LLC Full Holdings List — 2026 Q1

Stock History Sector / Type Port % Prev % Rank / Prev Conviction
Freshness
Change % Change Influence Shares Mkt Value Avg Cost Price Held 1st Owned Source Source Date Date Reported
PRAX
PRAXIS PRECISIO...
Healthcare 19.30% 16.62% #1 1
Prev: #2
6.5
1,865 2.2%
P
S
84,901 $27,354,253
$50.98 +570.8%
$322.19 +6.1%
2023 Q4 13F Filing 2026-03-31 2026-05-15
TERN
TERNS PHARMACEU...
Healthcare 18.44% 17.48% #2 1
Prev: #1
5.5
-141,323 -22.2%
P
S
495,772 $26,137,100
$11.06 +378.9%
$52.72 +0.4%
2022 Q3 13F Filing 2026-03-31 2026-05-15
WHWK
WHITEHAWK THERA...
Healthcare 8.30% 5.60% #3 2
Prev: #5
5.3
no change no change
P
S
3,410,402 $11,765,887
$15.31 -70.7%
$3.45 +30.1%
2021 Q3 13F Filing 2026-03-31 2026-05-15
TNGX
TANGO THERAPEUT...
Healthcare 6.52% 1.70% #4 10
Prev: #14
6.1
159,099 56.3%
P
S
441,831 $9,243,105 2025 Q4 13F Filing 2026-03-31 2026-05-15
DRUG
BRIGHT MINDS BI...
Healthcare 5.76% 4.48% #5 1
Prev: #6
5.3
27,519 32.6%
P
S
111,996 $8,172,348 2024 Q4 13F Filing 2026-03-31 2026-05-15
STRO
SUTRO BIOPHARMA...
Healthcare 4.73% 0.53% #6 18
Prev: #24
4.9
201,974 299.4%
P
S
269,425 $6,711,377 2018 Q4 13F Filing 2026-03-31 2026-05-15
ERAS
ERASCA INC
Healthcare 4.05% #7
Prev: #—
5.1
354,575
NEW
354,575 $5,737,024 2026 Q1 13F Filing 2026-03-31 2026-05-15
SRZN
SURROZEN INC
Healthcare 3.55% 2.74% #8 3
Prev: #11
1.9
-5,568 -3.1%
P
S
172,847 $5,035,033 2025 Q1 13F Filing 2026-03-31 2026-05-15
OCUL
OCULAR THERAPEU...
Healthcare 3.54% 8.68% #9 5
Prev: #4
1.4
-460,887 -43.8%
P
S
592,108 $5,015,155 2022 Q2 13F Filing 2026-03-31 2026-05-15
CMPX
COMPASS THERAPE...
Healthcare 3.17% 3.99% #10 3
Prev: #7
1.3
-244,224 -22.3%
P
S
849,076 $4,491,612 2025 Q3 13F Filing 2026-03-31 2026-05-15
NERV
MINERVA NEUROSC...
Healthcare 3.02% 1.94% #11 2
Prev: #13
2.2
no change no change
P
S
709,500 $4,274,738 2025 Q4 13F Filing 2026-03-31 2026-05-15
MLTX
MOONLAKE IMMUNO...
Healthcare 2.52% 0.53% #12 11
Prev: #23
4.0
132,480 223.5%
P
S
191,760 $3,574,406 2022 Q4 13F Filing 2026-03-31 2026-05-15
ARGX
ARGEN SE - ADR
Healthcare 2.42% 2.77% #13 3
Prev: #10
1.5
-161 -3.3%
P
S
4,690 $3,424,873 2017 Q2 13F Filing 2026-03-31 2026-05-15
OCS
OCULIS HOLDING ...
Healthcare 1.84% 1.38% #14 3
Prev: #17
1.2
-3,438 -3.4%
P
S
98,339 $2,614,834 2025 Q1 13F Filing 2026-03-31 2026-05-15
RVMD
REVOLUTION MEDI...
Healthcare 1.79% 0.45% #15 11
Prev: #26
3.7
17,658 209.9%
P
S
26,069 $2,535,210 2023 Q4 13F Filing 2026-03-31 2026-05-15
FDMT
4D MOLECULAR TH...
Healthcare 1.59% #16
Prev: #—
4.1
242,255
NEW
242,255 $2,255,394 2020 Q4 13F Filing 2026-03-31 2026-05-15
AMLX
AMYLYX PHARMACE...
Healthcare 1.48% 2.73% #17 5
Prev: #12
0.6
-182,191 -54.7%
P
S
151,067 $2,099,831 2025 Q3 13F Filing 2026-03-31 2026-05-15
TSHA
TAYSHA GENE THE...
Healthcare 1.39% 1.70% #18 3
Prev: #15
1.1
-15,363 -3.4%
P
S
439,464 $1,964,404 2023 Q3 13F Filing 2026-03-31 2026-05-15
IDYA
IDEAYA BIOSCIEN...
Healthcare 1.13% #19
Prev: #—
4.0
48,234
NEW
48,234 $1,607,157 2022 Q3 13F Filing 2026-03-31 2026-05-15
DSGN
DESIGN THERAPEU...
Healthcare 1.10% 0.96% #20 2
Prev: #18
0.9
-5,006 -3.3%
P
S
145,900 $1,552,376 2025 Q4 13F Filing 2026-03-31 2026-05-15
UTHR
UNITED THERAPEU...
Healthcare 0.93% 0.76% #21 1
Prev: #20
0.9
-72 -3.1%
P
S
2,224 $1,318,788 2018 Q1 13F Filing 2026-03-31 2026-05-15
IDYA
IDEAYA BIOSCIEN...
CALL
CALL Option 0.82% #22
Prev: #—
3.8
350
NEW
350 $1,166,200 2022 Q3 13F Filing 2026-03-31 2026-05-15
TRDA
ENTRADA THERAPE...
Healthcare 0.80% #23
Prev: #—
3.8
89,358
NEW
89,358 $1,127,698 2026 Q1 13F Filing 2026-03-31 2026-05-15
AVTX
AVALO THERAPEUT...
Healthcare 0.64% #24
Prev: #—
3.8
60,808
NEW
60,808 $907,863 2026 Q1 13F Filing 2026-03-31 2026-05-15
LBRX
LB PHARMACEUTIC...
Healthcare 0.50% 0.45% #25 2
Prev: #27
0.7
-1,081 -3.6%
P
S
28,919 $713,143 2025 Q3 13F Filing 2026-03-31 2026-05-15
MAZE
MAZE THERAPEUTI...
Healthcare 0.41% 0.56% #26 4
Prev: #22
0.7
-665 -3.3%
P
S
19,335 $577,150 2025 Q4 13F Filing 2026-03-31 2026-05-15
UNCY
UNICYCIVE THERA...
Healthcare 0.27% 0.23% #27 2
Prev: #29
0.6
-2,026 -3.4%
P
S
57,959 $381,370 2024 Q3 13F Filing 2026-03-31 2026-05-15
NUVB/WS
NUVATION BIO IN...
Unknown 0.00% 0.02%
Sold All 😨
(Was: #30)
0.0
-90,832 -100.0%
CLOSED
$— 2021 Q1 13F Filing 2026-03-31 2026-05-15
KTTA
PASITHEA THERAP...
Healthcare 0.00% 0.39%
Sold All 😨
(Was: #28)
0.0
-450,000 -100.0%
CLOSED
$— 2025 Q4 13F Filing 2026-03-31 2026-05-15
DNTH
DIANTHUS THERAP...
Healthcare 0.00% 0.47%
Sold All 😨
(Was: #25)
0.0
-16,708 -100.0%
CLOSED
$— 2025 Q3 13F Filing 2026-03-31 2026-05-15
VSTM
VERASTEM INC
Healthcare 0.00% 0.75%
Sold All 😨
(Was: #21)
0.0
-143,446 -100.0%
CLOSED
$— 2023 Q2 13F Filing 2026-03-31 2026-05-15
INBX
INHIBRX BIOSCIE...
Healthcare 0.00% 0.88%
Sold All 😨
(Was: #19)
0.0
-16,377 -100.0%
CLOSED
$— 2025 Q3 13F Filing 2026-03-31 2026-05-15
ZYME
ZYMEWORKS INC
Healthcare 0.00% 1.43%
Sold All 😨
(Was: #16)
0.0
-80,143 -100.0%
CLOSED
$— 2024 Q4 13F Filing 2026-03-31 2026-05-15
INSM
INSMED INC
Healthcare 0.00% 3.06%
Sold All 😨
(Was: #9)
0.0
-25,878 -100.0%
CLOSED
$— 2014 Q4 13F Filing 2026-03-31 2026-05-15
JAZZ
JAZZ PHARMACEUT...
Healthcare 0.00% 3.35%
Sold All 😨
(Was: #8)
0.0
-29,008 -100.0%
CLOSED
$— 2025 Q1 13F Filing 2026-03-31 2026-05-15
CDTX
CIDARA THERAPEU...
Unknown 0.00% 13.37%
Sold All 😨
(Was: #3)
0.0
-89,145 -100.0%
CLOSED
$— 2024 Q4 13F Filing 2026-03-31 2026-05-15
Showing 1-36 of 36 holdings

Unlock Full ACUTA CAPITAL PARTNERS, LLC Analysis

PRO subscribers get access to all historical quarters, Excel/CSV exports, Portfolio Concentration Analytics (PCA), and Risk-Based ENB.

Full Historical Quarters
Excel & CSV Export
PCA & Risk-Based ENB
Auto Cost Basis
Position Change Alerts
Price-Held Analytics
Full history →